Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

6.74
+0.35005.48%
Post-market: 6.800.0600+0.89%19:51 EST
Volume:6.45M
Turnover:42.73M
Market Cap:618.58M
PE:4.14
High:6.78
Open:6.42
Low:6.32
Close:6.39
52wk High:19.70
52wk Low:6.18
Shares:91.78M
Float Shares:87.27M
Volume Ratio:1.56
T/O Rate:7.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.63
EPS(LYR):-0.5920
ROE:66.13%
ROA:-0.59%
PB:1.93
PE(LYR):-11.39

Loading ...

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia

GlobeNewswire
·
Sep 29, 2025

Coherent Introduces Next-Gen 2D VCSEL and Photodiode Arrays To Accelerate AI-Driven Optical Interconnects

GlobeNewswire
·
Sep 25, 2025

Press Release: Annovis Appoints Mark Guerin as Chief Financial Officer

Dow Jones
·
Sep 25, 2025

Does Renaissance's Exit Signal Deeper Competitive Challenges for PagerDuty (PD) in Software Growth?

Simply Wall St.
·
Sep 24, 2025

Anker to Launch 45W Display-Equipped Charging Head on September 27: Features Foldable Plugs and Expected PD 3.2 AVS Protocol Support

Deep News
·
Sep 23, 2025

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

GlobeNewswire
·
Sep 23, 2025

CSTONE PHARMA-B (02616): CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) Phase II Clinical Trial Completes First Patient Enrollment in Australia

Stock News
·
Sep 23, 2025

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

GlobeNewswire
·
Sep 18, 2025

HENLIUS (02696): First Patient Dosed in Australia for International Multi-center Phase 2 Clinical Study of HLX43 (PD-L1 Targeted Antibody-Drug Conjugate) for Advanced Non-Small Cell Lung Cancer Treatment

Stock News
·
Sep 18, 2025

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

GlobeNewswire
·
Sep 18, 2025

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

GlobeNewswire
·
Sep 17, 2025

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

GlobeNewswire
·
Sep 16, 2025

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

GlobeNewswire
·
Sep 16, 2025

HENLIUS (02696): FDA Approves Clinical Trial Application for Pembrolizumab Biosimilar HLX17 in Patients with Multiple Resected Solid Tumors

Stock News
·
Sep 08, 2025

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)

GlobeNewswire
·
Sep 05, 2025

Hong Kong Stock Alert | ABBISKO-B (02256) Opens High Over 6% Hitting Record High, Company Benefits from Multiple Positive Catalysts as Oral PD-L1 Combination with Glecirasib Receives Phase II Clinical Approval

Stock News
·
Sep 05, 2025

PagerDuty's H2 Outlook Buoyed by Pricing Moves Despite User Reductions, RBC Says

MT Newswires Live
·
Sep 05, 2025

BUZZ-U.S. STOCKS ON THE MOVE- Gap, Aquestive Therapeutics, Lumentum

Reuters
·
Sep 04, 2025

PagerDuty Shares Climb 4.9%

THOMSON REUTERS
·
Sep 04, 2025

Stock Track | PagerDuty Soars 5% Despite Lowered Annual Forecast and Mixed Analyst Reactions

Stock Track
·
Sep 04, 2025